Montville, NJ-based Berlex Laboratories has received Food and Drug Administration approval to market its Magnevist MRI contrast agent in prefilled syringes. The contrast company expects to begin shipments of the syringes in the first quarter of 1999.
Montville, NJ-based Berlex Laboratories has received Food and Drug Administration approval to market its Magnevist MRI contrast agent in prefilled syringes. The contrast company expects to begin shipments of the syringes in the first quarter of 1999. Prefilled syringes will come in 10-mL, 15-mL, and 20-mL sizes. Berlex believes that prefilled syringes will save time and reduce the potential for contamination and needle stick incidents that might occur when Magnevist syringes are filled manually.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.